Copyright © 2004, European Society of Cardiology
Effects of ACE inhibitor and AT1 blocker on dystrophin-related proteins and calpain in failing heart
aDepartment of Pharmacology, Tokyo University of Pharmacy and Life Science, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan
bDepartment of Organ Pathophysiology and Internal Medicine, Tokyo University Hospital, Tokyo, Japan
* Corresponding author. Tel.: +81 426 76 4583; fax: +81 426 76 5560. Email address: takeos{at}ps.toyaku.ac.jp
Objectives: Genetic depletion of dystrophin-related protein (DRP) complex causes cardiomyopathy in animals and humans. We found in a previous study that some types of DRP were degraded and that calpain content was increased in rats with non-genetically induced heart failure. The present study was aimed at examining the effects of an angiotensin-I-converting enzyme inhibitor (ACEI) trandolapril (Tra) or an angiotensin II type 1 receptor blocker (ARB) candesartan (Can), both of which are known to improve the pathophysiology of chronic heart failure (CHF) on degradation of DRP in failing hearts.
Methods: Coronary artery-ligated (CAL) and sham-operated rats (Sham rats) were treated orally with 3 mg/kg/day trandolapril (Tra) or 1 mg/kg/day candesartan (Can) from the 2nd to 8th week after surgery.
Results: Hemodynamic parameters of CAL rats at the 8th week after CAL (8w-CAL) indicated heart failure. 
-Sarcoglycan (SG) and dystrophin in the surviving left ventricle (surviving LV) of 8w-CAL rats decreased, whereas β-, 
-, and 
-SGs remained unchanged. Calcium-activated neutral proteases µ-calpain and m-calpain increased in the surviving LV at the 8th week of postmyocardial infarction. Proteolytic activity in the presence of 5 mM Ca2+ markedly increased at the 2nd and 8th weeks, whereas 50 µM Ca2+ slightly but significantly increased proteolysis of casein. Tra or Can treatment improved the hemodynamic parameters, attenuated changes in -SG and dystrophin, and reversed both calpain contents and activities of the failing heart back to sham levels.
Conclusion: These results suggest that attenuation in calpain-induced degradation of DRP complex is a possible mechanism for the Tra- or Can-mediated improvement of the pathogenesis of CHF following myocardial infarction.
KEYWORDS Experimental; Heart; Organ and subcellular; Pathophysiology; Candesartan; Dystrophin; Heart failure; Sarcoglycan; Trandolapril
Time for primary review 26 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Honda, F. Masui, N. Kanzawa, T. Tsuchiya, and T. Toyo-oka Specific knockdown of m-calpain blocks myogenesis with cDNA deduced from the corresponding RNAi Am J Physiol Cell Physiol, April 1, 2008; 294(4): C957 - C965. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nattel, A. Maguy, S. Le Bouter, and Y.-H. Yeh Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation Physiol Rev, April 1, 2007; 87(2): 425 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Baudet Pathophysiology of heart failure: more bricks in the "crumbling sarcolemmal scaffolding" paradigm? Cardiovasc Res, February 1, 2005; 65(2): 299 - 301. [Full Text] [PDF]
|
|